IDYA — IDEAYA Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1676725 ·
Last close
$35.50
Market Cap
$3.42B
52W High
$40.58
52W Low
$26.81
ADV30
1,199,593
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 10,876,000 | — | -94,570,000 | -83,273,000 | 1,109,324,000 | 112,825,000 | 86,390,000 |
| Sep 2025 | 207,834,000 | — | 108,452,000 | 119,244,000 | 1,185,136,000 | 298,927,000 | 93,102,000 |
| Jun 2025 | 0 | — | -88,806,000 | -77,491,000 | 1,041,270,000 | 114,645,000 | 81,617,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-71,098,000
Investing CF
$69,976,000
Financing CF
$29,779,000
CapEx
$-2,368,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.60
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-736,539,000
Inventory
—
Receivables
$5,973,000
ST Investments
$526,563,000
EBIT TTM
$-74,924,000
Pretax Income TTM
$-41,520,000
Interest Exp TTM
—
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$225,270,000
EBITDA
$-180,680,000
Free Cash Flow
$-57,254,500
Enterprise Value
$2,476,461,568
Total Cash
$671,201,024
Total Debt
$28,600,000
Shares Out
96,274,802
Trailing EPS
$-1.57
Book Value
$10.67
ROE
-14.3%
ROA
-10.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 218,710,000 | -159,313,000 | -113,698,000 | 1,109,324,000 | 86,390,000 | — | -71,098,000 |
| Dec 2024 | 7,000,000 | -326,975,000 | -274,477,000 | 1,124,091,000 | 64,944,000 | — | -247,584,000 |
| Dec 2023 | 23,385,000 | -134,429,000 | -112,961,000 | 649,316,000 | 28,226,000 | — | -115,224,000 |
| Dec 2022 | 50,931,000 | -62,502,000 | -58,655,000 | 387,969,000 | 38,514,000 | — | -87,175,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.64
Max Pain — expiry 2026-08-21
max pain strike: $35.00 · spot: $35.50 · call oi: 575 · put oi: 449
Expected Move to 2026-08-21:
±$3.12
(8.80%) —
implied range
$32.38 –
$38.62
· ATM straddle on $35.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GPCR | Structure Therapeutics Inc. | $3.41B | $48.04 | — |
| KNSA | Kiniksa Pharmaceuticals International, plc | $3.44B | $74.34 | — |
| GRTX | Galera Therapeutics, Inc. | $3.38B | $16.28 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.36B | $26.86 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.35B | $9.89 | — |
News headlines (Yahoo Finance, 1h cache)
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-07-31 10:00 · Yahoo
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancer
2026-07-27 10:00 · Yahoo
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
2026-07-17 13:00 · Yahoo
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
2026-06-17 10:00 · Yahoo
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
2026-06-15 10:00 · Yahoo
Ideaya Biosciences (IDYA) Forms Clinical Partnership With Roche for IDE892 Efficacy Study
2026-06-11 10:20 · Yahoo
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2026-06-10 20:05 · Yahoo
Tango Therapeutics (TNGX) Stock Soars on Pancreatic Cancer Trial Results
2026-06-09 13:29 · Yahoo
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Amid Inflation Data
2026-06-09 13:04 · Yahoo
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
2026-06-09 02:22 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.